Acute myocardial infarction with cardiogenic shock on admission: Incidence, prognostic implications, and current treatment strategies: Results from 'The 60-Minutes Myocardial Infarction Project'

Herz

Volumn 24, Issue 5, 1999, Pages 369-377

  Beermann, Werner ^a   Carlsson, Joerg ^b   Rustige, Jörg ^b   Schiele, Rudolf ^b   Senges, Jochen ^b   Tebbe, Ulrich ^b  

^a Katholisches Krankenhaus   (Germany)

^b NONE

Author keywords

Acute myocardial infarction; Cardiogenic shock; Thrombolytic therapy

Indexed keywords

FIBRINOLYTIC AGENT;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CARDIOGENIC SHOCK; FEMALE; FIBRINOLYTIC THERAPY; HOSPITAL ADMISSION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOMES RESEARCH; PROGNOSIS; RESUSCITATION; SYSTOLIC BLOOD PRESSURE;

EID: 0032699058     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03043928     Document Type: Article

References (29)

1. Alonso DR, Scheidt S, Post M, et al. Pathophysiology of cardiogenic shock. Quantification of myocardial necrosis, clinical, pathologic and electrocardiographic correlations. Circulation 1973;48:588-96.
2. Bates ER, Topol EJ. Limitations of thrombolytic therapy for acute myocardial infarction complicated by congestive heart failure and cardiogenic shock. J Am Coll Cardiol 1991;18:1077-84.
3. Becker RC. Hemodynamic, mechanical, and metabolic determinants of thrombolytic efficacy: A theoretic framework for assessing the limitations of thrombolysis in patients with cardiogenic shock. Am Heart J 1993;125:919-29.
4. Bengtson JR, Kaplan AJ, Pieper KS, et al. Prognosis in cardiogenic shock afler acute myocardial infarction in the interventional era. J Am Coll Cardiol 1992;20:1482-9.
5. Berger PB, Holmes DR, Stebbins AL, et al. Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-I) trial. An observational study. Circulation 1997;96:122-7.
6. Chiu Wong S, Liu JE, Jiang X, et al. Are there gender differences in clinical outcomes for patients with cardiogenic shock? A report from the SHOCK trial registry. Circulation 1997;96:Suppl: I-534.
7. Col NF, Gurwitz JH, Alpert JS, et al. Frequency of inclusion of patients with cardiogenic shock in trials of thrombolytic therapy. Am J Cardiol 1994;73:149-57.
8. Domanski MJ, Topol EJ. Cardiogenic shock: current understandings and future research directions. Am J Cardiol 1994;74:724-6.
9. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-22.
10. Goldberg RJ, Gore JM, Alpert JS, et al. Cardiogenic shock after acute myocardial infarction. Incidence and mortality from a community-wide perspective, 1975 to 1988. N Engl J Med 1991;325: 1111-22.
11. Greenbaum RA, Morris R, Sritara P, et al. Reduced in-hospital mortality from acute myocardial infarction with general adoption of thrombolytic treatment in the North West Thames health region 1979-1991. Br Heart J 1995;74:493-6.
12. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarcto Miocardico. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 Patients with acute myocardial infarction. Lancet 1990; 336:65-71.
13. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;I: 397-401.
14. Gutovitz AL, Sobel BE, Roberts R. Progressive nature of myocardial injury in selected patients with cardiogenic shock. Am J Cardiol 1978;41:469-75.
15. Hibbard MD, Holmes DR, Bailey KR, et al. Percutaneous transluminal coronary angioplasty in patients with cardiogenic shock. J Am Coll Cardiol 1992;19:639-46.
16. Holmes DR, Bates ER, Kleiman NS, et al. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. J Am Coll Cardiol 1995;26:668-74.
17. Kaplan AJ, Bengtson JR, Aronson LG, et al. Reperfusion improves survival in patients with cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol 1990;15:155A.
18. Lee L, Bates ER, Pitt B, et al. Percutaneous transluminal coronary angioplasty improves survival in acute myocardial infarction complicated by cardiogenic shock. Circulation 1988;78:1345-51.
19. Lee L, Erbel R, Brown TM, et al. Multicenter registry of angioplasty therapy of cardiogenic shock: initial and long-term survival. J Am Coll Cardiol 1991;17:599-603.
20. Moosvi AR, Gheorghiade M, Goldstein S, et al. Management of cardiogenic shock complicating acute myocardial infarction: the Henry Ford Hospital experience and review of the literature. Henry Ford Hosp Med J 1991;39:240-4.
21. Morissette M, Gagnon RM, Laramée P, et al. In-hospital prognosis of cardiogenic shock resulting from acute myocardial infarction in women. Circulation 1993;88:I-253.abstract.
22. Muller DWM, Topol EJ. Selection of patients with acute myocardial infarction for thrombolytic therapy. Ann Intern Med 1990; 113:949-60.
23. O'Neill WW. Angioplasty therapy of cardiogenic shock: are randomized trials necessary? J Am Coll Cardiol 1992;19:915-7.
24. Page DL, Caulfield JB, Kastor J, et al. Myocardial changes associated with cardiogenic shock. N Engl J Med 1971;285:133-7.
25. Rustige J, Schiele R, Burczyk U, et al., for the ALKK Study Group. The 60 Minutes Myocardial Infarction Project. Treatment and clinical outcome of patients with acute myocardial infarction in Germany. Eur Heart J 1997;18:1438-46.
26. Scheidt S, Ascheim R, Killip III T. Schock after acute myocardial infarction. A clinical and hemodynamic profile. Am J Cardiol 1970;26:556-64.
27. Second International Study of Infarct Survival Collaborative Group (ISIS-2). Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17 187 cases of suspected acute myocardial infarction. Lancet 1988;II:349-60.
28. The International Study Group. In-hospital mortality and clinical course for 20.891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990;336:71-5.
29. Wilcox R G, von der Lippe G, Olsson CG, et al., for the ASSET (Anglo-Scandinavian Study of Early Thrombolysis) Study Group. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction (ASSET). Lancet 1988;II: 525-30.